PAH treatment Opsynvi endorsed by patients, clinicians
Treatment with Opsynvi (macitentan and tadalafil) as a single-tablet combination therapy for people with pulmonary arterial hypertension (PAH) is highly valued by patients and endorsed by clinicians, according to interviews conducted during the Phase 3 A DUE trial. All patients interviewed said that a single, once-a-day pill to…